Correlation of Clinical Progress and Serum Prostate Specific Antigen in the Treatment of Chronic Prostatitis / 대한비뇨기과학회지

ABSTRACT

Purpose: We compared the baseline and post-treatment serum prostate specific antigen levels (s-PSA), the expressed prostatic secretion (EPS) and the chronic prostatitis symptom index (CPSI). We wanted to determine whether the serum PSA level could be used as a biochemical marker for checking the progress of patients with chronic prostatitis. Materials and Methods: Of the patients who diagnosed with chronic prostatitis, we respectively reviewed the records of 48 men who were under 50 years old and who presented with a serum PSA level lower than 4ng/ ml (group P). As a control group (group N), we used the s-PSA data obtained from 2,787 men under 50 years old who had no evidence for lower urinary infection, and these men were seen at a serial screening program of a primary health clinic. After the treatment with antibiotics and nonsteroidal anti-inflammatory agents, the serum PSA and EPS were rechecked every 4 weeks. The National Institutes of Health (NIH)-CPSI scores were rechecked after 8 weeks. Results: There are no different at mean age (group P vs N; 41.1 vs 41.1 years old). The baseline average serum PSA in group P was 1.53+/-0.73 ng/ml, and that in group N was 0.85 0.81ng/ml; the difference was significant (p=0.001). After 8 weeks of treatment, the average post-treatment serum PSA level was significantly decreased to 1.22+/-0.59ng/ml (p<0.05) and the leukocyte count in the EPS was also significantly decreased (p<0.05). The total NIH-CPSI score was significantly improved (p<0.05). Conclusions: These data suggest that serum PSA is increased in chronic prostatitis patients. Antibiotics and nonsteroidal anti-inflammatory treatment can relief patients' symptoms as well as decrease the serum PSA for chronic prostatitis after 8 weeks. Therefore, serum PSA could be used as a diagnostic factor in determining the patients' progress with employing the CPSI score and EPS results.